The role of antiseptic agents in atopic dermatitis

Melissa Lee; Hugo Van Bever

doi:10.5415/apallergy.2014.4.4.230

Journal List > Asia Pac Allergy > v.4(4) > 1060846

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee and Van Bever: The role of antiseptic agents in atopic dermatitis

Hypothesis & Experience

Asia Pacific Allergy 2014; 4(4): 230-240.

Published online: 29 October 2014

DOI: https://doi.org/10.5415/apallergy.2014.4.4.230

The role of antiseptic agents in atopic dermatitis

Melissa Lee, Hugo Van Bever

Department of Paediatrics, University Children's Medical Institute, Yong Loo Lin School of Medicine, Singapore 119077, Singapore.

Correspondence: Melissa Lee. Department of Paediatrics, University Children's Medical Institute, Yong Loo Lin School of Medicine, National University of Singapore, 21 Lower Kent Ridge Road, Singapore 119077, Singapore. Tel: +61 421 872 961, Fax: +61 8 93122348, leeps.melissa@gmail.com

Received 30 April 2014 Accepted 12 September 2014

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The skin of individuals with atopic dermatitis has a susceptibility to be colonized with Staphylococcus aureus. This has been associated with increased frequency and severity of exacerbations of atopic dermatitis. Therefore, there is a growing interest in the use of antiseptic agents to target primary bacterial colonization and infection. Antiseptic agents have been found to be better tolerated and less likely to induce bacterial resistance as compared to antibiotics. There is also a wide variety of antiseptic agents available. The efficacy of antiseptic agents has yet to be established as the studies reviewed previously have been small and of suboptimal quality. This review discusses the rationale behind targeting S. aureus with antiseptic agents and presents findings from a review of studies assessing the efficacy of antiseptics in atopic dermatitis in the last five years. Four studies were found, including a bleach bath study which has already been reviewed elsewhere. The remaining 3 studies assessed the efficacy of sodium hypochlorite containing cleansing body wash, sodium hypochlorite baths and 1% triclosan in leave on emollient. These studies suggested some benefit for the inclusion of antiseptic use with the mainstay management of atopic dermatitis, including a potential steroid sparring effect. However, there are many limitations to these studies which therefore warrant further investigation on the impact of antiseptic use in atopic dermatitis.

Keywords: Staphylococcus aureus, Atopic dermatitis, Anti-infective agents, local

INTRODUCTION

Atopic dermatitis (AD) is a chronic, relapsing and remitting inflammatory skin condition that usually develops in early childhood. Data derived from the International study of asthma and allergies in childhood (ISAAC) has shown a worldwide prevalence ranging from 2% to 20% with a tendency for higher prevalence in affluent European and Australasian settings, and rising eczema burden in most developing country settings and in younger children [1, 2, 3]. Diagnosis depends on clinical assessment and the National Institute for Health and Care Excellence (NICE) guideline recommends the use of the validated criteria for AD (Table 1), which was derived from the Hanifin and Rajka diagnostic criteria [4, 5]. Most cases of childhood AD are mild with infrequent exacerbations and minimal impact to quality of life. However, more severe AD is correlated with poorer overall health, impaired sleep and increased healthcare utilization [6, 7]. There also appears to be an association between severe AD and multiple comorbid chronic health disorders, both atopic and nonatopic, such as asthma, hay fever, food allergies, recurrent ear infections, visual problems and impaired dental hygiene [6, 7].

Much remains to be understood about the complex pathophysiology of AD, however, it is widely accepted that the skin commensal microorganism Staphylococcus aureus (SA) has an important role in the disease process [8]. The skin of patients with atopic eczema has a tendency to be colonized by SA [8, 9, 10, 11, 12]. This bacteria has been isolated from up to 90% of lesional skin [13, 14, 15] and has also been found in clinically uninfected areas, as well as in several reservoirs such as the anterior nares, the axillae and the perianal region [16, 17] in patients with AD. It has been reported that self-contamination from these reservoir sites or colonized skin lesions can be as high as 73% [18, 19, 20]. In comparison, SA can be isolated from the skin of 5-30% of unaffected individuals [17, 21, 22, 23]. Colonization with SA within the first year of life has been linked to AD prevalence in the first and second years of life and poses a 4.29-fold risk of moderate to severe AD in early childhood, although this link has been disputed [24, 25]. Staphylococcal colonization also persists despite eradication strategies with studies showing recurrence in almost 100% of patients with eczema after antistaphylococcal treatment, with pathogenic strains being reisolated after months of adequate treatment [17, 26]. Family members also often serve as a source of rapid recolonization [27]. The clinical significance of colonization is that there may be a correlation between SA colonization with severity and exacerbation of disease [11, 12, 22].

STAPHYLOCOCCAL COLONIZATION IN ATOPIC ECZEMA

Extensive research has shown that the propensity for SA colonization is complex and multifactorial [12]. It has been suggested that the underlying allergic skin inflammation of AD may contribute to increased colonization of SA as skin inflammation injures the skin barrier and exposes extracellular matrix adhesins which facilitate SA adherence [12]. The role of inflammation and bacterial adherence is based on studies showing significantly reduced colonization on the skin following topical anti-inflammatory drugs alone, such as corticosteroids or calcineurin inhibitors [28, 29, 30, 31]. There is also an understanding that individuals with skin disease may be genetically predisposed to microscopic structural changes in the skin barrier, including increased synthesis of extracellular matrix adhesins, fibronectin and fibrinogen for SA [32, 33], reduced skin lipid content, an alkaline skin surface pH [34, 35, 36] and reduced production of endogenous antimicrobial peptides due to defective innate immune responses [10, 12]. Collectively, this skin barrier dysfunction enhances SA colonization. It also allows the entry of SA superantigens (SSAgs), as well as allergens and irritants, thus contributing to exacerbation of skin disease [10].

SSAgs are exotoxins produced by SA which play a key role in the chronic inflammatory nature of AD. They have the ability to trigger an enhanced inflammatory response through the stimulation of a variety of T-cell clones and cytokine secretions [12]. Over 70% of SA strains isolated from the skin of AD patients produce superantigens such as alpha-toxin, toxic shock syndrome toxin-1 and staphylococcal enterotoxins and their role has been established in several immunohistological studies based on SA strains isolated from the lesional skin of patients with AD [26, 37, 38, 39]. Increased levels of antistaphylococcal superantigen specific IgE and IgM antibodies, in addition to cytokines such as interleukin (IL) 4 and interferon-γ, have also been quantified in the sera of most patients with AD compared to normal controls and have been shown to decrease with treatment [11, 40]. There is also a positive correlation between colonization with superantigen producing strains of SA and clinical severity of AD [41, 42]. SSAgs can also induce corticosteroid resistance, which may increase the severity of skin disease [43, 44]. This has led to the hypothesis that eradication of SA may lead to a steroid sparring effect [11], which is an incentive to management as long term topical corticosteroid use may lead to adverse effects such as local irritation, skin atrophy and skin depigmentation [5].

There is also an emerging role on the impact of environmental proteases in the pathogenesis of AD. SA, in addition to environmental allergens such as cockroaches, dust mites, pollen and fungi, also produce proteases which may enhance the passage of allergens across the skin barrier, or act as allergens themselves, and contribute to the inflammatory response [45]. Extracellular proteases produced by SA, such as serine-, cysteine- and metalloproteases [46, 47], have been found in in vivo mice studies to compromise the epidermal permeability barrier [48]. These bacterial proteases are also insensitive to and have the ability to inactivate some human plasma proteases inhibitors and interact with host defense mechanisms and tissue components in a complex manner that further augments the infection process and enhances SA survival [46, 47].

SA infection is therefore related to the pathogenesis of eczema (Table 2). Consequently, there is a theoretical basis for the eradication of SA in patients with eczema in order to prevent aggravation of skin disease.

THE RATIONALE FOR ANTISEPTIC USE IN ATOPIC ECZEMA

There has been wide interest in the use of antistaphylococcal agents as ancillary therapy for the management of AD. Treatment strategies can be divided into the management of clinically infected skin disease and the prophylactic treatment of individuals who are at risk of colonization or infection, and ranges from the use of systemic and topical antibiotics as well as antiseptic agents [49, 50]. Antiseptics represent an alternative to topical antibiotics in patients with AD. The main advantages of antiseptics over antibiotics are that they have low potential of inducing bacterial resistance, rarely cause delayed-type hypersensitivities or allergic reactions and come in a variety of preparations to suit individual needs. Antiseptics include triclosan, potassium permanganate, sodium hypochlorite or bleach and chlorhexidine gluconate [49]. It is widely accepted that disease flares caused by secondary infection with SA requires and responds to treatment with antibiotics and antiseptic agents [11, 51, 52]. However, good scientific data on the subject are rare. Clinically infected or 'impetiginised' skin disease can be characterized by increased erythema, superficial pustular eruption or purulent exudation with crusting and can spread easily [5]. Antiseptic baths can be particularly useful in reducing crusting and consequently, bacterial load [49]. Antibiotic treatment alone has no impact on allergic skin inflammation although a number of studies showed that topical or systemic antibiotics were able to reduce colonization density, resulting in partial improvement of skin lesions [17, 53, 54]. The NICE guideline recommends a one to two weeks course of flucloxicillin as first-line treatment to treat widespread infection with SA in children with atopic eczema [5]. Topical antibiotics, including preparations combined with topical corticosteroids, can be used for no longer than two weeks in patients with clinical infection in localized areas. However, the benefit of antibiotic use in AD is still disputed with a Cochrane review presenting studies showing no significant difference in global outcome for clinically infected eczema when oral antibiotics were compared with placebo or when topical steroid antibiotic combinations were compared with steroid alone [50]. Given the contradictory results available, it would be prudent to be restrictive in prescribing antibiotics, mainly because of an increasing resistance problem worldwide [55, 56, 57, 58].

For children with AD and are prone to recurrent infections, the short term use of antiseptics, such as triclosan or chlorhexidine, can also be used as adjunct therapy to reduce bacterial load [5]. One percent to 2% triclosan or 0.5% to 1% chlorhexidine added to emollient may be applied on a daily basis on the whole body or on affected areas. Alternatively, twice weekly antiseptic bathes have been recommended [49]. However, it appears that the recommendations for the topical use of antibiotics and antiseptics are not substantiated by good quality clinical data [49, 50].

Antiseptics in clinically infected eczema

In a Cochrane review released in 2010, Bath-Hextall et al. [50] and Birnie et al. [50, 59] performed a systemic review of 26 randomized controlled trials (RCTs), involving 1,229 participants, of interventions to reduce SA in eczema to determine whether they were superior than standard therapy in clinically infected or clinically uninfected atopic eczema. The review found one RCT assessing the effect of an antibacterial bath additive on clinically infected AD. This study by Huang et al. [51] involved 31 children with clinically infected moderate to severe AD who were pretreated with oral cephalexin then treated with either intranasal mupirocin ointment and bleach baths (treatment arm) or intranasal petrolatum ointment and plain water baths (placebo arm) for 3 months. Whilst the RCT concluded that there was reduced clinical severity of clinically infected AD in the treatment arm based on eczema area and severity index (EASI) scores (7.9 points, p = 0.017 at 1 month; 12.1 points, p = 0.004 at 3 months), the study was criticized as it was unclear if any adjustment was made for the differing baseline EASI scores between the two group of patients who were treated for more than one month (26.9 in the treatment group and 17.7 in the placebo group) [50, 51]. Of further clinical relevance is that eradication of SA was not achieved despite pretreatment with daily cephalexin for 2 weeks followed by 3 months of twice daily intranasal mupirocin treatment for 5 consecutive days each month and twice weekly bleach baths [51]. With regards to the use of topical antiseptic agents, the Cochrane review found one poorly reported study assessing the benefit of povidone-iodine in 15 children and adults with clinically infected mild to moderate AD but was unable to perform a group analysis [50].

Topical antiseptics in clinically uninfected eczema

The role of antistaphylococcal agents used preventively in the setting of uninfected skin in AD against exacerbation is less clear and remains a controversial area in the management of AD, particularly with the fears of the emergence of antibiotic-resistant strains of SA [56, 60]. Therefore, antiseptics used in this setting may be a suitable alternative as they have less potential to induce resistance [49]. The Cochrane review reported a lack of good quality large RCTs and found that there is no good evidence to support the use of antistaphylococcal agents in uninfected eczema [50]. A review by Schnopp et al. [49] presented 15 studies which assessed the efficacy of a range of antiseptic treatments including triclosan, chlorhexidine, didecyldimethylammoniumchloride, povidone iodine, bleach, silk coated textiles and special silk fabric. However, differing endpoints, inclusion criteria and treatment protocol in the studies made it challenging to determine the benefit of antibacterial therapy in AE. A key finding was the importance of anti-inflammatory therapy and its role in reducing bacterial colonization.

AN UPDATED REVIEW OF STUDIES ASSESSING ANTISEPTIC USE IN ATOPIC ECZEMA

Given the growing potential of antiseptic use in AE, we reviewed studies assessing the efficacy of antiseptics in AD in the last five years (to March 2014). PubMed was searched for studies in English containing bleach, triclosan, chlorhexidine, sodium hypochlorite, povidone iodine or potassium permanganate and eczema or AD. The efficacy of fabrics treated to provide antimicrobial activity was not assessed in this review. The results were hand searched for relevant studies, with 4 studies found, Table 3, including the bleach bath study by Huang et al. [51] which has already been reviewed [49, 50].

Sodium hypochlorite in AD management

It appears that there is growing interest in the role of sodium hypochlorite in the management of AD. Its antistaphylococcal activity, including against methicillin-resistant SA, has been established in in vitro and in vivo studies, with concentrations as low as 0.005% being shown to be safe and effective [61, 62, 63, 64]. Its antimicrobial effect is probably due its ability to cause irreversible aggregation of essential bacterial proteins [65]. Traditional dilute bleach baths have concentrations that range from 50 parts per million (ppm; 0.005%; equivalent to 0.25 cup bleach in half a tub of water) to 90 ppm (0.009%; equivalent to half a cup of bleach in half a tub of water) [66]. Furthermore, sodium hypochlorite is better tolerated, is easily accessible and cheaper compared to other antiseptic agents [49].

In a pilot feasibility study, Ryan et al. [66] assessed the efficacy of a 0.0061% sodium hypochlorite containing cleansing body wash in 18 children with clinically uninfected moderate to severe AD who also had lesional cultures positive for SA at baseline. Patients used the wash three days a week for 12 weeks and were allowed to continue with their individualized topical and systemic treatment regimen. Clinical response was measured using an investigator global assessment (IGA) score and the percentage of body surface area (BSA) affected. Acceptability and tolerability of the product was also assessed retrospectively using a questionnaire completed by parents [66]. The use of sodium hypochlorite gel cleanser was reported to result in statistically significant mean reductions in IGA scores at all follow-up time points-1.0 at 2 weeks (p = 0.01, n = 6), 0.8 at 1 month (p = 0.005, n = 11), 0.8 at 2 months (p = 0.01, n = 12), and 0.9 at 3 months (p = 0.002, n =13). The overall mean reduction in IGA score from baseline to final measurement was 0.9 (p = 0.001, n = 18). The mean reduction from baseline of BSA affected was 10.7% at 2 weeks (p = 0.22, n = 6), 10.9% at 1 month (p < 0.001, n = 11), 14.6% at 2 months (p = 0.001, n = 12), and 16.8% at3 months (p = 0.01, n = 13). The overall mean reduction from baseline to final measurement in all patients was 14.8% (p = 0.005, n =18). A statistically significant reduction in bacterial count was found at 1 month only (p = 0.01, n = 10), despite following a decreasing trend. There were no reports of patients developing infective exacerbations requiring oral antibiotic treatment during the course of the study. The use of sodium hypochlorite gel cleanser was also highly accepted and tolerated by patients and their parents with high scores recorded on the patient satisfaction questionnaire. Patients also unanimously preferred this product over traditional dilute sodium hypochlorite bleach baths [66]. The authors acknowledged that the limitations of the study were that it was a small non blinded study that lacked a placebo arm and had many of the retrospective patients in the initial phase of the study lost to follow up [66]. A larger randomized controlled study assessing the clinical efficacy of sodium hypochlorite containing body wash is thus needed to confirm the encouraging results of this pilot study and should include the impact on the usage of the patient's topical and systemic regimen and whether it has any benefit in clinically infected AD.

Wong et al. [67] performed a 2-month prospective randomized, double-blinded, placebo-controlled study assessing the efficacy of 0.005% sodium hypochlorite baths in 36 patients aged between 2 and 30 years old with uninfected moderate to severe AD. Patients were given either 100mL of 5% sodium hypochlorite (bleach treatment arm) or distilled water (placebo arm) and instructed to add this into 100 L of water. They were instructed to soak neck down in these baths for 10 minutes, twice a week for two months. Patients then rinsed off with normal tap water and were allowed to maintain their individualized regimen of topical anti-inflammatory and emollient therapy. Aqueous cream as soap was provided to standardize their bathing regimen. Follow-up was performed at baseline, week 2, week 4, and week 8 (end) of treatment [67]. Response to treatment was assessed using the EASI score, a validated composite score of BSA from four regions (head and neck, upper limbs, trunk and lower limbs) and a physician's assessment of erythema, edema/induration/papulation, excoriation and lichenification on a 4-point scale. Patients' assessment of overall response and intensity of itch was assessed using visual analog scale and bacteriological assessment was performed by calculating SA density from a swab of the worst affected sites. Safety based on clinical adverse events reported by patients or observed by the physician was also assessed [67]. Overall, the study reported that the use of diluted bleach baths resulted in clinically improved AD from 1 month and was tolerated by patients. The study reported a significant reduction in EASI scores between the treatment and placebo groups at 1 and 2 months (p < 0.001) suggesting clinical improvement was achieved and sustained after 1 month of treatment. There was also significant improvement in EASI scores and various clinical parameters corresponding to the upper limbs, trunk and lower limbs (areas of the body submerged in the baths) at 2 months in the treatment group. Whilst the head and neck of patients in the treatment group showed improvement in the above outcomes, this was not statistically significant and may have been due to partial submersion of these areas. The improvement in EASI scores in the treatment group also corresponded to a significant reduction in percentage BSA affected at 2 months (p = 0.002). These improvements appeared to be evident across all age groups [67]. The use of bleach baths was also associated with a reduction in density of SA over time, although this was not statistically significant. There was also no statistical difference in colony counts between the treatment and placebo groups at either 1 or 2 months. These findings were similarly found in the bleach bath study by Huang et al. [51] suggesting that clinically improvement in AD does not require complete eradication of SA [67]. There were no statistically significant differences in patient's overall assessment of response between treatment and placebo groups at either 1 or 2 months. Of patients in the treatment group, 27.8% experienced side effects which included burning/stinging and mild dry skin. A similar proportion of patients in the placebo group also experienced similar side effects. No patients withdrew from the study because of intolerance to the baths [67]. Limitations of this study were that it was a small study with short treatment and follow-up and since patients were responsible for administering their own treatment, the study was not performed in a controlled environment. Furthermore, this study was not a true double blinded study as patients would have been able to differentiate between bleach and placebo on the basis of odour. This was recognized by Huang et al. [51] in their own bleach bath study. Future studies also need to further assess the relationship between degree of SA colonization and clinical severity of AD since it appears complete eradication of SA colonization may not be necessary for disease improvement. Whilst dilute sodium hypochlorite is bactericidal in vitro [62], persistent colonization despite treatment in patients may reflect recolonization from sites not exposed to the antiseptic, such as the nares, or from members of the household who may be carriers. Improvement in disease may also reflect a shift in skin flora, as opposed to being solely related to reduction in SA colonization, as suggested in a separate study assessing the temporal shifts in the skin microbiome associated with disease flares and treatment in children with AD [68]. Based on ribosomal RNA bacterial gene sequencing performed on DNA obtained directly from serial skin sampling of children with AD, it was found SA was greater during disease flares and correlated with worsened disease severity and that AD treatments diversify skin bacteria preceding improvements in disease activity [68].

Triclosan in AD management

One study presented in this review was a double blinded RCT assessing the efficacy of emollient containing 1% triclosan in 60 patients with mild to moderate uninfected AD [69]. It was reported that emollient containing 1% triclosan significantly reduced AD severity at day 14 compared to vehicle control, as determined by mean SCORAD change from baseline (-8.86 vs.-4.75, p < 0.05), and was found to be safe and highly acceptable to patients after a study period of 27 days. Adverse events were reported in 15 patients however only 4 were considered related to treatment and included transient stinging pain after application of 1% triclosan containing emollient. This resolved spontaneously even with continued use of the cream. There were no subjects who withdrew from the study due to adverse events [69]. There was also improvement of severity at day 27 in the treatment group, however this was not significant (-11.46, 95% CI, 15.2-8.1 for treatment group vs. -9.71, 95% CI, 13.06-5.99 for control group; p > 0.05) [69]. A low potency corticosteroid was allowed to be used concurrently during the treatment period and interestingly, the authors reported significantly lower amount of topical steroid application by patients in the treatment group compared to the control (22 g and 44.2 g, respectively; p < 0.05), thus implying a steroid sparring and synergistic effect of 1% triclosan containing emollient [69]. It has been suggested that the reduction of SA colonization associated with antiseptic use produces this steroid sparring effect by reducing local SA enterotoxin induced corticosteroid resistance [43, 44]. Since this study was performed in patients with clinically uninfected eczema, no bacteriological analysis was performed [69]. Therefore, this putative effect requires further investigation as there is also a paucity of long term, good quality studies assessing the relationship between the reduction in SA colonization with antimicrobials, its impact on amount of corticosteroid used, whether it has any implications to corticosteroid potency required and how it affects clinical outcome.

CONCLUSIONS

As the skin of patients with AD has intrinsic properties that increase susceptibility to SA colonization, it is unlikely that the use of antistaphylococcal therapy alone, with the aim of eradicating primary infection, will be of long-term benefit, particularly with the high rates of recolonization. Optimal management requires addressing the key factors known to cause exacerbation of disease, primarily targeting improvement in skin barrier function and reducing skin inflammation. Consequently, the mainstay of AD management, which constitutes irritant and allergen avoidance, emollients to enable the repair and protection of the skin barrier with proper hydration and topical anti-inflammatory agents such as corticosteroids or calcineurin inhibitors, will remain important therapeutic options (Table 4) [70, 71]. The use of emollients and topical corticosteroids alone are able to reduce microbial colonization thus reducing the risk of secondary infection and the need for specific antimicrobial therapy [8, 72]. There is also an emerging rationale for a 'proactive' approach to the management of AD to achieve long-term remission between flares. This involves continued intermittent application of low dose topical anti-inflammatory agent over previously eczematous but now normal looking skin, together with daily application of emollient [73]. Again, this is based on the recognition that normal appearing skin is not immunologically normal and is often colonized by SA [8, 73, 74]. However, the proactive approach of topical anti-inflammatory agents is considered 'offlabel' use and the adverse effects of their long-term use cannot be ignored. It may also be difficult to achieve patient compliance thus hindering the reported benefits of this 'proactive' approach.

The studies available on the role of antiseptic agents in the management of AD suggest some benefit for the inclusion of antiseptic use. However, there are many limitations to these studies which therefore warrant further investigation on the impact of antiseptic use in AD. The approach of adding antiseptic agents to emollients and body washes is a convenient measure of introducing an additional agent into the AD management regimen. Future studies need to be large scale double blinded RCTs and should assess long-term efficacy, safety, tolerability and cost effectiveness. In particular, these studies should assess whether any flares or infected exacerbations occur with continued antiseptic use. The reported steroid sparring effect associated with antiseptic use should also be further investigated.

Figures and Tables

Table 1

Diagnostic criteria of atopic dermatitis^* [4]

^*Reproduced from National Institute for Health and Care Excellence. Atopic Eczema in Children, Clinical Guideline No.57 London: National Institute for Health and Clinical Excellence; 2007, with the permission of the Royal College of Obstetricians and Gynaecologists on behalf of the National Collaborating Centre for Women's and Children's Health.

^†Asian, black Caribbean, and black African children may have atopic eczema affecting the extensor surfaces rather than the flexures, and discoid or follicular patterns may be more common.

Table 2

Summary of potential mechanisms by which Staphylococcus aureus induces and exacerbates atopic dermatitis [12, 45]

IL, Interleukin; SSAg, Staphylococcal superantigen; APC, antigen presenting cell; TNF, tumour necrosis factor; CLA+, cutaneous lymphocyte-associated antigen; ECM, extracellular matrix; AD, atopic dermatitis; SA, Staphylococcus aureus; Th, T helper cell.

Table 3

Antiseptic treatment

AD, atopic dermatitis; IGA, investigator global assessment; BSA, body surface area; EASI, eczema area and severity index; SCORAD, SCORing Atopic Dermatitis.

^*Diagnosis based on Hanifin and Rajka Criteria. ^†Weeping, crusting and/or pustule.

Table 4

Practical conclusions for the clinician [5, 10, 71]

TCI, topical calcineurin inhibitors; SA, Staphylococcus aureus.

References

1. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009; 124:1251–1258.e23.

2. Flohr C. Recent perspectives on the global epidemiology of childhood eczema. Allergol Immunopathol (Madr). 2011; 39:174–182.

3. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR. International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008; 121:947–954.e15.

4. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh). 1980; 92:Suppl. 44–47.

5. National Institute for Health and Care Excellence. NICE guidelines [CG57]. Atopic eczema in children: management of atopic eczema in children from birth up to the age of 12 years. London: NICE;c2014. cited 2014 Mar 9. Available from: http://guidance.nice.org.uk/CG57/Guidance/pdf/English.

6. Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013; 24:476–486.

7. Cox H, Lloyd K, Williams H, Arkwright PD, Brown T, Clark C, Campbell M, Gore C, Hardman C, Langford A, Lewis-Jones S, Lawton S, Ridd M, Russell L, Sohi D, Turnbull R, Venter C, Warner JO. Science and Research Department, Royal College of Paediatrics and Child Health. Emollients, education and quality of life: the RCPCH care pathway for children with eczema. Arch Dis Child. 2011; 96:Suppl 2. i19–i24.

8. Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010; 125:4–13.

9. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003; 361:151–160.

10. Farhi D, Taieb A, Tilles G, Wallach D. The historical basis of a misconception leading to undertreating atopic dermatitis (eczema): facts and controversies. Clin Dermatol. 2010; 28:45–51.

11. Gong JQ, Lin L, Lin T, Hao F, Zeng FQ, Bi ZG, Yi D, Zhao B. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006; 155:680–687.

12. Lin YT, Wang CT, Chiang BL. Role of bacterial pathogens in atopic dermatitis. Clin Rev Allergy Immunol. 2007; 33:167–177.

13. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol. 1974; 90:525–530.

14. Leyden JJ, Kligman AM. The case for steroid: antibiotic combinations. Br J Dermatol. 1977; 96:179–187.

15. Aly R, Maibach HI, Shinefield HR. Microbial flora of atopic dermatitis. Arch Dermatol. 1977; 113:780–782.

16. Mempel M, Lina G, Hojka M, Schnopp C, Seidl HP, Schafer T, Ring J, Vandenesch F, Abeck D. High prevalence of superantigens associated with the egc locus in Staphylococcus aureus isolates from patients with atopic eczema. Eur J Clin Microbiol Infect Dis. 2003; 22:306–309.

17. Breuer K, HAussler S, Kapp A, Werfel T. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol. 2002; 147:55–61.

18. Hon KL, Lam MC, Leung TF, Kam WY, Li MC, Ip M, Fok TF. Clinical features associated with nasal Staphylococcus aureus colonisation in Chinese children with moderate-to-severe atopic dermatitis. Ann Acad Med Singapore. 2005; 34:602–605.

19. Falanga V, Campbell DE, Leyden JJ, Douglas SD. Nasal carriage of Staphylococcus aureus and antistaphylococcal immunoglobulin E antibodies in atopic dermatitis. J Clin Microbiol. 1985; 22:452–454.

20. Kim KH, Hwang JH, Park KC. Periauricular eczematization in childhood atopic dermatitis. Pediatr Dermatol. 1996; 13:278–280.

21. Hauser C, Wuethrich B, Matter L, Wilhelm JA, Sonnabend W, Schopfer K. Staphylococcus aureus skin colonization in atopic dermatitis patients. Dermatologica. 1985; 170:35–39.

22. Goh CL, Wong JS, Giam YC. Skin colonization of Staphylococcus aureus in atopic dermatitis patients seen at the National Skin Centre, Singapore. Int J Dermatol. 1997; 36:653–657.

23. Arslanagic N, Arslanagic R. Atopic dermatitis and Staphylococcus aureus. Med Arh. 2004; 58:363–365.

24. Lebon A, Labout JA, Verbrugh HA, Jaddoe VW, Hofman A, van Wamel WJ, van Belkum A, Moll HA. Role of Staphylococcus aureus nasal colonization in atopic dermatitis in infants: the Generation R Study. Arch Pediatr Adolesc Med. 2009; 163:745–749.

25. Skov L, Halkjaer LB, Agner T, Frimodt-Moller N, Jarlov JO, Bisgaard H. Neonatal colonization with Staphylococcus aureus is not associated with development of atopic dermatitis. Br J Dermatol. 2009; 160:1286–1291.

26. Hoeger PH, Lenz W, Boutonnier A, Fournier JM. Staphylococcal skin colonization in children with atopic dermatitis: prevalence, persistence, and transmission of toxigenic and nontoxigenic strains. J Infect Dis. 1992; 165:1064–1068.

27. Bonness S, Szekat C, Novak N, Bierbaum G. Pulsed-field gel electrophoresis of Staphylococcus aureus isolates from atopic patients revealing presence of similar strains in isolates from children and their parents. J Clin Microbiol. 2008; 46:456–461.

28. Pournaras CC, Lubbe J, Saurat JH. Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506). J Invest Dermatol. 2001; 116:480–481.

29. Remitz A, Kyllonen H, Granlund H, Reitamo S. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol. 2001; 107:196–197.

30. Stalder JF, Fleury M, Sourisse M, Rostin M, Pheline F, Litoux P. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol. 1994; 131:536–540.

31. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol. 1992; 27:29–34.

32. Cho SH, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW, Leung DY. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol. 2001; 116:658–663.

33. Cho SH, Strickland I, Boguniewicz M, Leung DY. Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin. J Allergy Clin Immunol. 2001; 108:269–274.

34. Sator PG, Schmidt JB, Honigsmann H. Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J Am Acad Dermatol. 2003; 48:352–358.

35. Kita K, Sueyoshi N, Okino N, Inagaki M, Ishida H, Kiso M, Imayama S, Nakamura T, Ito M. Activation of bacterial ceramidase by anionic glycerophospholipids: possible involvement in ceramide hydrolysis on atopic skin by Pseudomonas ceramidase. Biochem J. 2002; 362(Pt 3):619–626.

36. Arikawa J, Ishibashi M, Kawashima M, Takagi Y, Ichikawa Y, Imokawa G. Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol. 2002; 119:433–439.

37. Akiyama H, Toi Y, Kanzaki H, Tada J, Arata J. Prevalence of producers of enterotoxins and toxic shock syndrome toxin-1 among Staphylococcus aureus strains isolated from atopic dermatitis lesions. Arch Dermatol Res. 1996; 288:418–420.

38. Bunikowski R, Mielke M, Skarabis H, Herz U, Bergmann RL, Wahn U, Renz H. Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. J Allergy Clin Immunol. 1999; 103(1 Pt 1):119–124.

39. McFadden JP, Noble WC, Camp RD. Superantigenic exotoxin-secreting potential of staphylococci isolated from atopic eczematous skin. Br J Dermatol. 1993; 128:631–632.

40. Breuer K, Wittmann M, Bosche B, Kapp A, Werfel T. Severe atopic dermatitis is associated with sensitization to staphylococcal enterotoxin B (SEB). Allergy. 2000; 55:551–555.

41. Bunikowski R, Mielke ME, Skarabis H, Worm M, Anagnostopoulos I, Kolde G, Wahn U, Renz H. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol. 2000; 105:814–819.

42. Zollner TM, Wichelhaus TA, Hartung A, Von Mallinckrodt C, Wagner TO, Brade V, Kaufmann R. Colonization with superantigen-producing Staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin Exp Allergy. 2000; 30:994–1000.

43. Roll A, Cozzio A, Fischer B, Schmid-Grendelmeier P. Microbial colonization and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2004; 4:373–378.

44. Hauk PJ, Hamid QA, Chrousos GP, Leung DY. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol. 2000; 105:782–787.

45. Takai T, Ikeda S. Barrier dysfunction caused by environmental proteases in the pathogenesis of allergic diseases. Allergol Int. 2011; 60:25–35.

46. Dubin G. Extracellular proteases of Staphylococcus spp. Biol Chem. 2002; 383:1075–1086.

47. Kantyka T, Shaw LN, Potempa J. Papain-like proteases of Staphylococcus aureus. Adv Exp Med Biol. 2011; 712:1–14.

48. Hirasawa Y, Takai T, Nakamura T, Mitsuishi K, Gunawan H, Suto H, Ogawa T, Wang XL, Ikeda S, Okumura K, Ogawa H. Staphylococcus aureus extracellular protease causes epidermal barrier dysfunction. J Invest Dermatol. 2010; 130:614–617.

49. Schnopp C, Ring J, Mempel M. The role of antibacterial therapy in atopic eczema. Expert Opin Pharmacother. 2010; 11:929–936.

50. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol. 2010; 163:12–26.

51. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009; 123:e808–e814.

52. Walling HW, Swick BL. Update on the management of chronic eczema: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol. 2010; 3:99–117.

53. Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DY. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol. 2001; 108:651–652.

54. Brockow K, Grabenhorst P, Abeck D, Traupe B, Ring J, Hoppe U, Wolf F. Effect of gentian violet, corticosteroid and tar preparations in Staphylococcus-aureus-colonized atopic eczema. Dermatology. 1999; 199:231–236.

55. Gomes PL, Malavige GN, Fernando N, Mahendra MH, Kamaladasa SD, Seneviratne JK, Karunatilaka DH, Ogg GS. Characteristics of Staphylococcus aureus colonization in patients with atopic dermatitis in Sri Lanka. Clin Exp Dermatol. 2011; 36:195–200.

56. Heng YK, Tan KT, Sen P, Chow A, Leo YS, Lye DC, Chan RK. Staphylococcus aureus and topical fusidic acid use: results of a clinical audit on antimicrobial resistance. Int J Dermatol. 2013; 52:876–881.

57. Petry V, Lipnharski C, Bessa GR, Silveira VB, Weber MB, Bonamigo RR, d'Azevedo PA. Prevalence of community-acquired methicillin-resistant Staphylococcus aureus and antibiotic resistance in patients with atopic dermatitis in Porto Alegre, Brazil. Int J Dermatol. 2014; 53:731–735.

58. Kedzierska A, Kapinska-Mrowiecka M, Czubak-Macugowska M, Wojcik K, Kedzierska J. Susceptibility testing and resistance phenotype detection in Staphylococcus aureus strains isolated from patients with atopic dermatitis, with apparent and recurrent skin colonization. Br J Dermatol. 2008; 159:1290–1299.

59. Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev. 2008; (3):CD003871.

60. Howden BP, Grayson ML. Dumb and dumber: the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis. 2006; 42:394–400.

61. Heggers JP, Sazy JA, Stenberg BD, Strock LL, McCauley RL, Herndon DN, Robson MC. Bactericidal and wound-healing properties of sodium hypochlorite solutions: the 1991 Lindberg Award. J Burn Care Rehabil. 1991; 12:420–424.

62. Sassone LM, Fidel RA, Murad CF, Fidel SR, Hirata R Jr. Antimicrobial activity of sodium hypochlorite and chlorhexidine by two different tests. Aust Endod J. 2008; 34:19–24.

63. McKenna PJ, Lehr GS, Leist P, Welling RE. Antiseptic effectiveness with fibroblast preservation. Ann Plast Surg. 1991; 27:265–268.

64. Fisher RG, Chain RL, Hair PS, Cunnion KM. Hypochlorite killing of community-associated methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J. 2008; 27:934–935.

65. Winter J, Ilbert M, Graf PC, Ozcelik D, Jakob U. Bleach activates a redox-regulated chaperone by oxidative protein unfolding. Cell. 2008; 135:691–701.

66. Ryan C, Shaw RE, Cockerell CJ, Hand S, Ghali FE. Novel sodium hypochlorite cleanser shows clinical response and excellent acceptability in the treatment of atopic dermatitis. Pediatr Dermatol. 2013; 30:308–315.

67. Wong SM, Ng TG, Baba R. Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. J Dermatol. 2013; 40:874–880.

68. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, Nomicos E, Polley EC, Komarow HD, Murray PR, Turner ML, Segre JA. NISC Comparative Sequence Program. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012; 22:850–859.

69. Tan WP, Suresh S, Tey HL, Chiam LY, Goon AT. A randomized double-blind controlled trial to compare a triclosan-containing emollient with vehicle for the treatment of atopic dermatitis. Clin Exp Dermatol. 2010; 35:e109–e112.

70. Jensen JM, Pfeiffer S, Witt M, Brautigam M, Neumann C, Weichenthal M, Schwarz T, Folster-Holst R, Proksch E. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2009; 123:1124–1133.

71. Abramovits W. A clinician's paradigm in the treatment of atopic dermatitis. J Am Acad Dermatol. 2005; 53:1 Suppl 1. S70–S77.

72. Hung SH, Lin YT, Chu CY, Lee CC, Liang TC, Yang YH, Wang LC, Chiang BL. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Ann Allergy Asthma Immunol. 2007; 98:51–56.

73. Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol. 2012; 24:253–260.

74. Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis: an emerging concept. Allergy. 2009; 64:276–278.

TOOLS

Similar articles